Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032.
The Feinstein Institute for Medical Research, Northwell Health, Manhasset, New York, NY 11030.
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):E2911-E2919. doi: 10.1073/pnas.1702564114. Epub 2017 Mar 17.
Activating mutations of (a well-known oncogene in T-cell acute lymphoblastic leukemia) are present in ∼4-13% of chronic lymphocytic leukemia (CLL) cases, where they are associated with disease progression and chemorefractoriness. However, the specific role of in leukemogenesis remains to be established. Here, we report that the active intracellular portion of NOTCH1 (ICN1) is detectable in ∼50% of peripheral blood CLL cases lacking gene mutations. We identify a "NOTCH1 gene-expression signature" in CLL cells, and show that this signature is significantly enriched in primary CLL cases expressing ICN1, independent of mutation. NOTCH1 target genes include key regulators of B-cell proliferation, survival, and signal transduction. In particular, we show that NOTCH1 transactivates via binding to B-cell-specific regulatory elements, thus implicating this oncogene in CLL development. These results significantly extend the role of in CLL pathogenesis, and have direct implications for specific therapeutic targeting.
(一种在 T 细胞急性淋巴细胞白血病中众所周知的癌基因)的激活突变存在于约 4-13%的慢性淋巴细胞白血病(CLL)病例中,与疾病进展和化疗耐药性相关。然而,NOTCH1 在白血病发生中的具体作用仍有待确定。在这里,我们报告在约 50%缺乏基因突变的外周血 CLL 病例中可检测到 NOTCH1 的活性细胞内部分(ICN1)。我们在 CLL 细胞中鉴定出一个“NOTCH1 基因表达特征”,并表明该特征在表达 ICN1 的原发性 CLL 病例中显著富集,与 NOTCH1 突变无关。NOTCH1 的靶基因包括 B 细胞增殖、存活和信号转导的关键调节剂。特别是,我们表明 NOTCH1 通过与 B 细胞特异性调节元件结合来反式激活 ,从而暗示该癌基因在 CLL 发育中起作用。这些结果显著扩展了 NOTCH1 在 CLL 发病机制中的作用,并对特定的治疗靶向具有直接影响。